ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and Safety of Oral Chinese Herbal Medicine for Migraine: A Systematic Review and Meta-Analyses Using Robust Variance Estimation Model

Lyu, Shaohua; Zhang, Claire Shuiqing; Guo, Xinfeng; Zhang, Anthony Lin; Sun, Jingbo; Chen, Genghang; Xue, Charlie Changli*; Luo, Xiaodong*广东省人民医院; 广州中医药大学
Frontiers in Neurology2022-7-6DOI: 10.3389/fneur.2022.889336
1被引24阅读
引用收藏
分享

摘要

Background: Migraine is a prevalent headache disorder with significant impacts on patients' quality of life and economic burden. Chinese herbal medicine (CHM) is commonly prescribed for migraine in China. This review aimed to provide a rigorous evaluation of evidence on the efficacy of oral CHM for migraine and explore the correlation between its effect size and treatment duration. Methods: We searched nine digital databases (PubMed, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, AMED, BioMedical Literature, CNKI, CQVIP, and Wanfang Data) from their inceptions to May 2021, with the language being restricted to Chinese and English. Randomized, placebo-controlled trials using oral CHM to treat adult migraine were included. Data screening and extraction were conducted by two independent reviewers. The methodological quality of randomized controlled trials (RCTs) was assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to estimate the effect size using a random effect model, and a robust variance estimation (RVE) model was constructed to explore the correlation between treatment effects and treatment duration. The certainty of the evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation. Publication bias was tested using a funnel plot and Egger's test. Results; A total of 18 RCTs involving 3,015 participants were included. Results of the meta-analyses showed that, at the end of the treatment phase, CHM was more efficacious than placebo in reducing migraine frequency, migraine days, and pain severity, and increasing response rate. Additionally, CHM showed superior effects to placebo in lowering migraine frequency and pain severity at the end of the 4-week follow-up. The RVE model suggested that the benefits of CHM for migraine frequency and pain intensity increased as treatment duration extended. The number of adverse events reported by the CHM and placebo groups was comparable. The certainty of the evidence was graded as "moderate. " No publication bias was detected. Conclusion: Oral CHM appeared to be more efficacious than placebo for reducing migraine frequency and pain severity. Greater treatment effects were associated with longer treatment duration. The oral CHM was well tolerated.

学科与关键词

关键词
migraineChinese herbal medicinesystematic reviewmeta-analysisrobust variance estimation
相关
加载中…
  • Real-world observations and impacts of Chinese herbal medicine for migraine: results of a registry-based cohort study
    Lyu, Shaohua; Zhang, Claire Shuiqing; Zhang, Anthony Lin; Guo, Xinfeng; Hua, Rong; Mao, Zhenhui; Su, Qiaozhen; Xue, Charlie Changli*; Sun, Jingbo*Frontiers in Pharmacology, 2024, 15: 1330589.
  • Traditional Chinese patent medicine for prophylactic treatment of migraine: a meta-analysis of randomized, double-blind, placebo-controlled trials
    Xiao Y; Yuan L; Liu Y; Sun X; Cheng J; Wang T; Li F; Luo R; Zhao X*European Journal of Neurology, 2015, 22(2): 361-368.
  • Migraine patients visiting Chinese medicine hospital: Protocol for a prospective, registry-based, real-world observational cohort study
    Lyu, Shaohua; Zhang, Claire Shuiqing; Zhang, Anthony Lin; Sun, Jingbo; Xue, Charlie Changli*; Guo, Xinfeng*PLoS One, 2022, 17(3): e0265137.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Neurology
发表日期
2022-07-06
卷期
第 13 卷
页码
889336
DOI
10.3389/fneur.2022.889336
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
China-Australia International Research Center for Chinese Medicine - Guangzhou University of Chinese Medicine Double First -Class and High-level University Discipline Collaborative Innovation Team [2021xk84, E43723]; China-Australia International Research Center for Chinese Medicine; Guangzhou University of Chinese Medicine Double First -Class and High-level University Discipline Collaborative Innovation Team [2021xk84]; Studio of Prof. Huang Huang based in Guangdong Provincial Hospital of Chinese Medicine [E43723]

作者

  • L

    Lyu, Shaohua (第一作者)

    guangdong prov acad chinese med sci · 2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zhang, Claire Shuiqing

查看全部 8 位作者收起作者
  • G

    Guo, Xinfeng

    guangdong prov acad chinese med sci · 2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zhang, Anthony Lin

  • S

    Sun, Jingbo

    guangdong prov acad chinese med sci · 2 · guangdong prov hosp · guangzhou univ chinese med

  • C

    Chen, Genghang

    guangdong prov acad chinese med sci · 2 · guangdong prov hosp · guangzhou univ chinese med

  • X

    Xue, Charlie Changli (通讯)

    guangdong prov acad chinese med sci · 2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Luo, Xiaodong (通讯)

    guangdong prov acad chinese med sci · 2 · guangdong prov hosp · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417